- Category
- Micro (2023-24)
- Udyam number
- UDYAM-UP-75-0057532

About Broswells Overseas Private Limited
Data last updated:
Broswells Overseas Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 19 March 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U74999DL2019PTC347438.
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh. It was formerly known as Broswell Overseas Private Limited. It is led by directors Anjana Mishra and Vaibhav Raj Mishra.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Wz – 186 F/F Vikash Puri, New Delhi, Delhi, India – 110018.
As per the financials filed for FY 2025, the company reported a revenue of ₹12.12 Lakh, a decline of 45% compared to the previous year. For the same year it recorded a net loss of ₹1.6 Lakh (net margin -13.2%) and EBITDA of ₹5,534 (EBITDA margin 0.5%). Revenue has grown at a compounded annual rate (CAGR) of 16% over three years and 56% over five years.
Broswells Overseas Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-UP-75-0057532). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website broswelloverseas.com.
Company details
Recognitions & Rankings of Broswells Overseas
Contact details
Broswells Overseas Private Limited's registered office is in New Delhi, Delhi. Its website is broswelloverseas.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressWz – 186 F/F Vikash Puri, New Delhi, Delhi, India – 110018
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Broswells Overseas Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Broswells Overseas is professional, scientific and technical. In detail, this covers advertising and market research.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M6 | Advertising and market research |
To see the full business activity and turnover split of Broswells Overseas Private Limited, buy the company report.
Financials of Broswells Overseas Private Limited
FY 2024 filings availableBroswells Overseas Private Limited reported revenue of ₹12.12 Lakh (down 45% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 45% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 56%. EBITDA fell 39% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹5,534 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹1.6 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 0.5% | ||||
| Net Profit Margin | -13.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Broswells Overseas Private Limited, buy the company report.
Board of directors of Broswells Overseas Private Limited
Broswells Overseas has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Anjana Mishra | Director | 19 Mar 2019 | 7 Years 7 Months | Current |
| Vaibhav Raj Mishra Also directs: Amsel Medicare Private Limited, Pay Panda Payment Solution Private Limited, Khwahishein Life Care Foundation and 1 more | Director | 19 Mar 2019 | 7 Years 7 Months | Current |
Peer comparison
Broswells Overseas Private Limited is compared with the 7 companies closest to it by revenue in the same principal business activity (advertising and market research), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Aiml Digital Analytics Private Limited | ₹12.16 Lakh (FY 2024) | Nagpur, Maharashtra, India | ||||
| Mikkel Marketing India Private Limited | ₹12.15 Lakh (FY 2018) | Noida, Uttar Pradesh, India | ||||
| Broswells Overseas Private Limitedthis company | ₹12.12 Lakh (FY 2025) | -₹1.6 Lakh | -13.2% | -45.0% | New Delhi, Delhi, India | |
| Vanon Marketing Private Limited | ₹12.11 Lakh (FY 2020) | New Delhi, Delhi, India | ||||
| Shobiz Integrated Marketing Communications Private Limited | ₹12.1 Lakh (FY 2017) | -58.0% | Mumbai, Maharashtra, India | |||
| Apurva Design and Advertising (OPC) Private Limited | ₹12.08 Lakh (FY 2022) | 23.0% | Chandigarh, India | |||
| NMN Adviser Solutions Private Limited | ₹12.07 Lakh (FY 2017) | 996.0% | Bangalore, Karnataka, India | |||
| Glitz Advertising Private Limited | ₹12.07 Lakh (FY 2025) | -22.0% | Delhi, India |
To see the full peer comparison of Broswells Overseas Private Limited, buy the company report.
Auditor
Broswells Overseas Private Limited is audited by Gupta Hemant & Co. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Gupta Hemant & Co. | FY 2023 | 031100N |
Shareholding
The shareholding of Broswells Overseas Private Limited is on record for 4 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Foreign institutional investors (FII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Broswells Overseas Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Broswells Overseas Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Broswells Overseas Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Broswells Overseas Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Broswells Overseas Private Limited has 2 board changes on record since 2019: 2 appointments. The latest: Anjana Mishra was appointed as Director on 19 Mar 2019.
Frequently asked questions
Broswells Overseas is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 19 March 2019 (7+ years old) and is registered under CIN U74999DL2019PTC347438.
Broswells Overseas has 2 current directors:
- Anjana Mishra - Director
- Vaibhav Raj Mishra - Director
The latest financial statements of Broswells Overseas on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from FY 2019 are in the company report.
The CIN (Corporate Identification Number) of Broswells Overseas is U74999DL2019PTC347438. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Broswells Overseas was incorporated on 19 March 2019, making it 7+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Broswells Overseas by revenue are Aiml Digital Analytics Private Limited, Mikkel Marketing India Private Limited, Vanon Marketing Private Limited, Shobiz Integrated Marketing Communications Private Limited, Apurva Design and Advertising (OPC) Private Limited and 2 more, all in the same principal business activity (advertising and market research).
Anjana Mishra was appointed as Director on 19 Mar 2019. Vaibhav Raj Mishra was appointed as Director on 19 Mar 2019.
Yes, Broswells Overseas is registered as a micro enterprise under Udyam registration (number: UDYAM-UP-75-0057532).
Broswells Overseas can be reached through the website broswelloverseas.com. Its registered office is in New Delhi, Delhi, India.
The registered office of Broswells Overseas is at Wz – 186 FF Vikash Puri, New Delhi, Delhi, India – 110018.
Broswells Overseas operates in the pharma industry, in the drug formulation and development segment.

